2016 Fiscal Year Final Research Report
The clarification of pathogenesis in polycystic kidney caused by feline PKD1 gene mutation and the specific therapy for PKD cats.
| Project/Area Number |
26450421
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Veterinary medical science
|
|---|
| Research Institution | Iwate University |
|---|
Principal Investigator |
Sato Reeko 岩手大学, 農学部, 教授 (80142892)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 常染色体優性多発性嚢胞腎 / PKD1遺伝子 / 猫 / ツーヒット / トルバプタン / ポリシスチン / CFTR |
|---|
| Outline of Final Research Achievements |
On the purpose of clarification of renal cyst formation in feline polycystic kidney disease (fPKD), PKD gene mutation (Exon29, c.10063, C>A) in cyst epithelium was analyzed and two-hit theory was discussed. Furthermore, molecularly-targeted drug for fPKD was selected and the clinical dosage for fPKD was also investigated.
Many blood samples and PKD kidney samples were collected through the feline polycystic kidney network, and PCR-RFLP analysis and direct sequence of PKD1 were performed. Homozygous mutation of PKD1 was found in cyst epithelium ( somatic cell ) suggesting two-hit mutation. Tolvaptan, orally active vasopressin V2 receptor antagonist, was selected for the molecularly-targeted therapy for fPKD and short-term and long-term administration of tolvaptan were performed in healthy cats for decision of clinical dosage.
|
| Free Research Field |
獣医内科学
|
